FDA approves Jazz's Vyxeos for AML

FDA approved Vyxeos (CPX-351) from Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to treat adults with two types of acute myelogenous leukemia -- newly diagnosed therapy-related AML (t-AML) and AML with myelodysplasia-related changes (AML-MRC).

Jazz expects to launch Vyxeos within a week, but could not be reached for pricing details. The drug's label includes a boxed warning not to interchange Vyxeos with other daunorubicin and/or cytarabine-containing products...